APLMW — Apollomics, Inc.

Summary of APLMW Q4 2023 Earnings Call

1. Key Financial Results and Metrics:

• Cash Position: As of December 31, 2023, cash and equivalents totaled $37.8 million, down from $58.9 million in 2022.
• Funding: Raised $23.7 million in March 2023 through a PIPE financing related to its business combination and NASDAQ listing.
• Expenses:
  • Research and Development (R&D) expenses were $34.2 million for 2023, slightly down from $35.4 million in 2022.
  • General and Administrative (G&A) expenses rose significantly to $20.6 million from $9.9 million in 2022, attributed to costs from becoming a public company and increased stock-based compensation.
• Net Loss: Reported a net loss of $172.6 million ($2.32 per diluted share), improved from a net loss of $240.8 million ($8.44 per diluted share) in 2022.
• Operating Cash Burn: Approximately $43.2 million used in operating activities, consistent with the prior year.

2. Strategic Updates and Business Highlights:

• Product Development: Significant progress in clinical trials for lead drug candidates, vebreltinib (APL-101) and APL-106.
  • Vebreltinib is in a Phase 2 registrational trial for non-small cell lung cancer (NSCLC) and other solid tumors with MET dysregulation.
  • The company has received conditional approval for vebreltinib in China for treating NSCLC with MET exon 14 skipping mutations.
  • APL-106, an e-selectin inhibitor for acute myeloid leukemia (AML), has completed patient enrollment for a Phase 3 bridging study in China.
• FDA Engagement: Positive feedback from a Type C meeting with the FDA regarding the development plan for vebreltinib, with a focus on expanding patient enrollment.

3. Forward Guidance and Outlook:

• The company expects to have sufficient cash to fund operations through Q1 2025.
• Anticipates submitting a New Drug Application (NDA) for vebreltinib in 2026, contingent on positive clinical data.
• Plans to present new preclinical data at the AACR meeting in April 2024 and expects top-line results for APL-106 in Q2 2024.

4. Bad News, Challenges, or Points of Concern:

• Cash Burn and Financial Health: The significant net loss and reduced cash reserves raise concerns about the sustainability of operations without additional funding.
• Regulatory Risks: The need for further patient enrollment to meet FDA requirements may delay timelines for NDA submissions.
• Increased Expenses: Rising G&A expenses could impact profitability and resource allocation for R&D.

5. Notable Q&A Insights:

• Enrollment Timeline: There is uncertainty regarding the timeline for patient enrollment and follow-up data, with potential implications for NDA submission timing.
• CFO Role: Newly appointed CFO Matthew Plunkett emphasized a focus on financial strategy and operational efficiency, particularly in navigating the company’s public reporting requirements.
• R&D Spending: Analysts inquired about R&D expenses, with indications that spending may increase due to ongoing clinical trials, but management suggested focusing on cash runway guidance for clarity.

Overall, Apollomics has made notable strides in its clinical development and regulatory engagements, but faces challenges related to financial sustainability and operational efficiency as it moves forward.